Medicine Man Technologies, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
Medicine Man Technologies, Inc. (Schwazze) entered a Restructuring Support Agreement to sell a majority of its assets to a Vireo Growth Inc. affiliate and liquidate remaining operations, following debt defaults.
OTC.Pink
Medicine Man Technologies, Inc. has appointed Philippe Faraut, an executive with over 25 years of experience, as its Interim Chief Financial Officer, effective July 14, 2025.
OTC.Pink
Medicine Man Technologies, Inc. announces the termination of employment of its Chief Policy and Regulatory Affairs Officer, Daniel Pabon, effective April 30, 2025, with a separation agreement in place.
OTC.Pink
Medicine Man Technologies, Inc. has appointed Bob Finley of FLG Partners as its Interim Chief Financial Officer, effective April 21, 2025, while the company continues its search for a permanent CFO.
OTC.Pink
Medicine Man Technologies' subsidiary, PBS Holdco, defaulted on a loan agreement, leading to the lender seizing $1.5 million from the subsidiary's bank accounts.
OTC.Pink
Medicine Man Technologies has reported a default on its debt obligations due to delayed financial filings and announced the appointment of Forrest Hoffmaster as CEO, while also planning a restatement of past financial results.
OTC.Pink
Schwazze, formerly Medicine Man Technologies, will restate its financial statements for fiscal years 2022 and 2023, and the first three quarters of 2023, due to identified accounting errors.
OTC.Pink
Schwazze announced second quarter 2024 financial results, showing sequential growth across key financial metrics despite a challenging market environment and restructuring efforts.
OTC.Pink
Schwazze has successfully restructured its debt obligations, extending maturity dates for both the Altmore Loan Agreement and the Reynold Greenleaf Promissory Note to November 2025.
OTC.Pink
Medicine Man Technologies, Inc., operating as Schwazze, will transition its common stock to the OTC Expert Market due to a delayed quarterly filing caused by issues with its previous auditor.
OTC.Pink
8-K: Medicine Man Technologies Holds 2024 Annual Meeting, Elects Directors and Approves Key Proposals
Medicine Man Technologies held its 2024 Annual Meeting, electing directors, ratifying its accountant, and approving increases to its equity incentive plan and authorized shares.
OTC.Pink
Schwazze announced a 4% increase in revenue for Q1 2024, but experienced a decrease in gross profit and adjusted EBITDA due to pricing pressures and increased operating expenses.
OTC.Pink
Medicine Man Technologies has dismissed BF Borgers CPA, PC and appointed Baker Tilly US, LLP as their new independent auditor, effective April 5, 2024.
OTC.Pink
8-K: Schwazze Reports Full Year 2023 Revenue of $172.4 Million, Achieves $53.4 Million Adjusted EBITDA
Schwazze announced its fourth quarter and full year 2023 financial results, highlighting $172.4 million in revenue and $53.4 million in adjusted EBITDA for the year.
OTC.Pink
Medicine Man Technologies, Inc., operating as Schwazze, announced the resignation of its CEO, Nirup Krishnamurthy, and the appointment of its CFO, Forrest Hoffmaster, as interim CEO.
OTC.Pink
Medicine Man Technologies has amended its previous 8-K filing to specify the board committees to which newly appointed director Kathy Vrabeck will serve.